Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Fermin Orgambide

MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance

MindMed Inc. (NASDAQ:MNMD) reported favorable results for one of its proprietary compounds.

The Phase 1 trial of MM-110 included 108 healthy volunteers and was designed to study the pharmacokinetics and neurocognitive effects of the substance, ensuring its safety and tolerability. MM-110 is designed to treat opioid withdrawal.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.